Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCS-01 Eye Drops in Diabetic Macular Edema
2023-507208-30-00Phase 3Completed
- Sponsor
- Oculis
- Start
- Sep 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing OCS-01 eye drops with Placebo eye drops (2 arms). Primary endpoints: Stage 1: Mean change in BCVA ETDRS letter score at Week 6 vs baseline and Stage 2: Mean change in BCVA ETDRS letter score at Week 52 vs baseline. Started Sep 2022; status: completed.
02
Drugs
OCS-01
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2023-507208-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507208-30-00.